In order to confirm EZH2 as a therapeutic target for the E.C.M. detached cancer cells, we decided to use an EZH2 methyltransferase activity inhibitor, namely GSK343, which is known to efficiently inhibit the activity of EZH2. Here, EZH2 is linked to cancer.